Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

70.46 -0.24 (-0.34%)
Streaming Delayed Price Updated: 11:43 AM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 151,315
Open 70.75
Bid (Size) 70.37 (1)
Ask (Size) 70.79 (2)
Prev. Close 70.70
Today's Range 69.95 - 71.46
52wk Range 47.86 - 107.37
Shares Outstanding 48,358,981
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government

Performance

YTD
-10.5%
-10.5%
1 Month
+9.9%
+9.9%
3 Month
+16.1%
+16.1%
6 Month
+4.4%
+4.4%
1 Year
+6.9%
+6.9%

More News

Read More
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
From Arcellx, Inc.
Via Business Wire
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
(ACLX) - Analyzing Arcellx's Short Interest
Via Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
Via Benzinga
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
From Arcellx, Inc.
Via Business Wire
Arcellx Provides First Quarter 2025 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
14 Analysts Have This To Say About Arcellx
Via Benzinga
Analyst Expectations For Arcellx's Future
Via Benzinga
Navigating 7 Analyst Ratings For Arcellx
Via Benzinga
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
From Arcellx, Inc.
Via Business Wire
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
From Arcellx, Inc.
Via Business Wire
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Arcellx
Via Benzinga
4 Analysts Assess Arcellx: What You Need To Know
Via Benzinga
Arcellx Stock Earns 82 Relative Strength Rating
Via Investor's Business Daily
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Via Investor's Business Daily
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Via Benzinga
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
From Arcellx, Inc.
Via Business Wire
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
From Arcellx, Inc.
Via Business Wire

Frequently Asked Questions

Is Arcellx, Inc. - Common Stock publicly traded?
Yes, Arcellx, Inc. - Common Stock is publicly traded.
What exchange does Arcellx, Inc. - Common Stock trade on?
Arcellx, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arcellx, Inc. - Common Stock?
The ticker symbol for Arcellx, Inc. - Common Stock is ACLX on the Nasdaq Stock Market
What is the current price of Arcellx, Inc. - Common Stock?
The current price of Arcellx, Inc. - Common Stock is 70.46
When was Arcellx, Inc. - Common Stock last traded?
The last trade of Arcellx, Inc. - Common Stock was at 07/17/25 11:43 AM ET
What is the market capitalization of Arcellx, Inc. - Common Stock?
The market capitalization of Arcellx, Inc. - Common Stock is 3.41B
How many shares of Arcellx, Inc. - Common Stock are outstanding?
Arcellx, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.